Although YY1 is not directly known to prompt the initiation of genomic instability, YY1 is a remarkable predictor of the outcome of breast cancer clonal selection, particularly in estrogen receptor (ER)-positive breast cancer patients undergoing hormone therapy. Here, ESR1 is linked to breast cancer.